Prof. Callewaert (2007)

Project details

Project start: 
2007
Pathology: 
Liver cirrhosis
University: 
Universiteit Gent (UGent)

Goal

Detecting the onset of early stage liver cirrhosis.

Why

Liver cirrhosis is usually a consequence of chronic liver disease (HBV/HCV induced) or chronic alcohol abuse and is characterized by abnormal structure and function of the liver. As liver cirrhosis is a major risk factor for the development of hepatocellular carcinoma (HCC), such early-stage liver cirrhosis diagnostic test can be used to identify those patients who need to be monitored for HCC more intensively.

Scientific project description

“GlycoCirrhoTest” is using the N-glycosylation of the total serum protein pool (the serum N- glycome) in liver patients.

 

Key findings

When used in combination with existing biomarkers, early stage cirrhosis (i.e. clinically compensated) can be diagnosed with approx. 60-70% sensitivity and >95% specificity (HCV etiology). As liver cirrhosis is a major risk factor for the development of hepatocellular carcinoma (HCC), such early-stage liver cirrhosis diagnostic test can be used to identify those patients who need to be monitored for HCC more intensively.

FFMI has funded studies to investigate whether the serum glycome contained information beyond GlycoCirrhoTest that could be useful in a cancer diagnostic context. Whereas the serum glycome yielded another biomarker that adds sensitivity to AFP screening for the detection of advanced HCC in cirrhosis patients, this new biomarker does not allow for earlier HCC detection and its clinical utility is therefore rather limited.

 

Status

  • IP secured
  • 7 papers published
  • FFM funding ended
  • Research-Use-Only kit under development (funded by IOF)

Budget

Final grant: € 266.250

Discovery
Qualification & Verification
Platform selection & Clinical Assay
Validation
Prof. Callewaert (2007)
Liver cirrhosis
serum